Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
Future Microbiol. 2021 Mar;16:317-322. doi: 10.2217/fmb-2020-0199. Epub 2021 Mar 12.
The host inflammatory response is critical in the progression of lung injuries in patients with SARS-CoV-2. Corticosteroids (CS) have been widely used as immunomodulating agents, but the right timing, dosage and type of molecule are unknown. In fact, the early use of CS could facilitate the viral replication but late administration may not prevent the alveolar damage. Nevertheless, a short administration of high doses of CS in the early stage of the inflammatory phase resulted in favorable outcomes. Noteworthy, some inhaled CS inhibited the viral replication of SARS-CoV-2. We aimed to define the place in therapy for CS in COVID-19 infection describing the features of patients who may benefit from their administration.
宿主炎症反应在 2019 冠状病毒病患者的肺部损伤进展中至关重要。皮质类固醇（CS）已被广泛用作免疫调节剂，但具体的使用时机、剂量和分子类型尚不清楚。事实上，CS 的早期使用可能会促进病毒复制，但晚期给药可能无法防止肺泡损伤。然而，在炎症早期阶段短期给予大剂量 CS 可带来有利的结果。值得注意的是，一些吸入性 CS 抑制了 SARS-CoV-2 的病毒复制。我们旨在通过描述可能从 CS 治疗中获益的患者特征，来确定 CS 在 COVID-19 感染治疗中的地位。
